Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;95(1):257-266.
doi: 10.1038/s41390-023-02792-y. Epub 2023 Sep 2.

Caffeine and kidney function at two years in former extremely low gestational age neonates

Matthew W Harer  1 , Russell Griffin  2 , David J Askenazi  2 , Mamta Fuloria  3 , Ronnie Guillet  4 , Mina Hanna  5 , Meredith P Schuh  6 , Cara Slagle  6 , Robert Woroniecki  7 ; Neonatal Kidney Collaborative Research Committee; Jennifer R Charlton  8
Collaborators, Affiliations

Caffeine and kidney function at two years in former extremely low gestational age neonates

Matthew W Harer et al. Pediatr Res. 2024 Jan.

Abstract

Background: Extremely low gestational age neonates (ELGANs) are at risk for chronic kidney disease. The long-term kidney effects of neonatal caffeine are unknown. We hypothesize that prolonged caffeine exposure will improve kidney function at 22-26 months.

Methods: Secondary analysis of the Preterm Erythropoietin Neuroprotection Trial of neonates <28 weeks' gestation. Participants included if any kidney outcomes were collected at 22-26 months corrected age. Exposure was post-menstrual age of caffeine discontinuation.

Primary outcomes: 'reduced eGFR' <90 ml/min/1.73 m2, 'albuminuria' (>30 mg albumin/g creatinine), or 'elevated blood pressure' (BP) >95th %tile. A general estimating equation logistic regression model stratified by bronchopulmonary dysplasia (BPD) status was used.

Results: 598 participants had at least one kidney metric at follow up. Within the whole cohort, postmenstrual age of caffeine discontinuation was not associated with any abnormal measures of kidney function at 2 years. In the stratified analysis, for each additional week of caffeine, the no BPD group had a 21% decreased adjusted odds of eGFR <90 ml/min/1.73m2 (aOR 0.78; CI 0.62-0.99) and the BPD group had a 15% increased adjusted odds of elevated BP (aOR 1.15; CI: 1.05-1.25).

Conclusions: Longer caffeine exposure during the neonatal period is associated with differential kidney outcomes at 22-26 months dependent on BPD status.

Impact: In participants born <28 weeks' gestation, discontinuation of caffeine at a later post menstrual age was not associated with abnormal kidney outcomes at 22-26 months corrected age. When assessed at 2 years of age, later discontinuation of caffeine in children born <28 weeks' gestation was associated with a greater risk of reduced eGFR in those without a history of BPD and an increased odds of hypertension in those with a history of BPD. More work is necessary to understand the long-term impact of caffeine on the developing kidney.

PubMed Disclaimer

Conflict of interest statement

COMPETING INTERESTS

All authors declare no real or perceived conflicts of interest that could affect the study design, collection, analysis, and interpretation of data, writing of the report, or the decision to submit for publication. For full disclosure, we provide here an additional list of other author’s commitments and funding sources that are not directly related to this study: M.W.H. receives research funding unrelated to this project from the NIH, Wisconsin Partnership Program, and Meriter Foundation. D.J.A. is a consultant for Baxter, Nuwellis, Medtronic Bioporto, and Seastar. His institution receives grant funding for education and research that is not related to this project from NIH, Baxter, Nuwellis, Medtronic, Bioporto, and Seastar. He has patents pending on inventions to improve the kidney care of neonates. He is the Founder and Chief Scientific Officer for Zorro-Flow. J.R.C. is a consultant for Medtronics and investor in Zorro-Flow. She receives funding for research not related to this project from the NIH. She is Vice-President of the Neonatal Kidney Collaborative. R.Guillet is a consultant for NEMA Research. She receives funding for research not related to this project from NIH. C.S. is a consultant for AM Pharma which is unrelated to the content in this manuscript. Meredith Schuh receives research funding unrelated to this project from NIH and Otsuka

Figures

Fig. 1
Fig. 1. Consort diagram.
Of 941 participants enrolled in the original trial, 598 subjects had a 22–26-month corrected age follow-up visit with at least one kidney metric obtained. The figure details participants who did not meet the inclusion criteria and the number who had specific kidney metrics obtained. eGFR estimated Glomerular Filtration Rate). Created with BioRender.com.
Fig. 2
Fig. 2. 22–26 month corrected gestational age kidney outcomes.
This histogram depicts frequencies of specific kidney outcomes by gestational age category. The x-axis displays the categories of kidney outcomes while the y axis is percent total of gestational age categories represented by the different bars with key beneath.
Fig. 3
Fig. 3. Last caffeine administration by post menstrual age.
This boxplot depicts the timing of caffeine discontinuation. The x-axis is the postmenstrual age of caffeine discontinuation, and the y axis is gestational age at birth.
Fig. 4
Fig. 4. Post menstrual age at caffeine discontinuation stratified by bronchopulmonary dysplasia status and follow-up at 22–26 months corrected gestational age.
This histogram depicts frequencies of the timing of caffeine discontinuation based on follow-up status and bronchopulmonary dysplasia (BPD) status. Each of the 4 panes represents a combination of those two possibilities: Follow-up with BPD, follow-up without BPD, no follow-up with BPD, and no follow-up without BPD. The x-axis is the postmenstrual age, and the y axis is number of study subjects.
See this image and copyright information in PMC

References

    1. Charlton JR, Baldelomar EJ, Hyatt DM & Bennett KM Nephron number and its determinants: a 2020 update. Pediatr. Nephrol 36, 797–807 (2021). - PMC - PubMed
    1. Jetton JG et al. Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. Lancet Child Adolesc. Health 1, 184–194 (2017). - PMC - PubMed
    1. Askenazi DJ et al. Prevalence of acute kidney injury (AKI) in extremely low gestational age neonates (ELGAN). Pediatr. Nephrol 35, 1737–1748 (2020). - PMC - PubMed
    1. Coca SG, Singanamala S & Parikh CR Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81, 442–448 (2012). - PMC - PubMed
    1. Mammen C. et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am. J. Kidney Dis 59, 523–530 (2012). - PubMed